Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Mitrabhanu, Mohanty
- Solubility improvement of Lapatinib by Novel Techniques of Solid Dispersion
Abstract Views :177 |
PDF Views:0
Authors
Affiliations
1 Natco Research Center, Natco Pharma Limited, Hyderabad-500018, IN
2 Sri Venkateshwara College of Pharmacy, Madhapur, Hyderabad-500081, IN
1 Natco Research Center, Natco Pharma Limited, Hyderabad-500018, IN
2 Sri Venkateshwara College of Pharmacy, Madhapur, Hyderabad-500081, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 4 (2019), Pagination: 1664-1676Abstract
Objective: Tyrosine kinase inhibitor, Lapatinib (LAP) is highly lipophilic in nature and presents challenges with regard to its low and variable oral bioavailability. Polymer-based solid dispersion technology has been considered as the major advancement in overcoming limited aqueous solubility and oral absorption issues. In the present research work, approaches were taken to improve the dissolution characteristics of LAP by developing suitable systems of solid dispersion. Methods: Solid dispersions of lapatinib were prepared utilizing techniques like solvent controlled coprecipitation, fusion, nanoprecipitation and spray drying. Polymers with different ionic characteristics like Eudragit® EPO (cationic), Eudragit® L 100 55 (anionic), HPMCP HP 55 (anionic), HPMC AS (anionic) and Povidone K 30 (non-ionic) were employed at three different ratios of 1:1, 1:2 and 1:3 to prepare the solid dispersions of weakly basic lapatinib. Dissolution study in media corresponding to different physiologically relevant pH was performed to understand the effectiveness of the technique and effect of the polymer. Additionally, samples were also subjected for X-ray powder diffraction study to understand the nature of the drug in the solid dispersion systems. Results: It was observed that irrespective of the pH of the dissolution media, the dissolution rate of solid dispersions of LAP prepared with anionic polymers in particular HPMCP HP 55 is more which is attributed to the weakly basic nature of lapatinib. The diffractograms show substantial decrease in the crystallinity of lapatinib in the solid dispersions. Conclusion: The combination of solid dispersion technique with supersaturable systems appears to hold promise for improving dissolution and bioavailability of poorly soluble drugs. Solid dispersions significantly increase dissolution of LAP, which can be a starting point of a new LAP formulation with improved bioavailability. The selection of polymers that can inhibit crystallization of LAP in a supersaturated state becomes the key factor for an effective formulation. The present work is an attempt in this direction.Keywords
Lapatinib, Polymers, Solid Dispersion, Supersaturable Systems, Insoluble Drugs.
References
- Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008; 129: 1–10.
- Lipinski CA. Drug like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 2000; 44: 235- 249.
- Leuner C. Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics. 2000; 50(1): 47–60.
- Jain S, Patel N, Lin S. Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug Dev Ind Pharm. 2015; 41: 875-887.
- Douroumis D, Fahr A. Drug Delivery Strategies for Poorly Water Soluble Drugs. Advances in Pharmaceutical Technology. Wiley Publication, UK. 2013.
- William R, Watts A, Miller D. Formulating Poorly Water Soluble Drugs. AAPS Advances in Pharmaceutical Science Series III. Springer Publication, NY. 2012.
- Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carr Sys. 2004; 21(3):133–193.
- Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001; 48: 27–42.
- Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res. 2010; 27: 2704-14.
- Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997; 86: 1–12.
- Baghel S, Cathcart H, O'Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016; 105: 2527–44.
- Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000; 50: 47–60.
- Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug–polymer miscibility and solubility. Pharm Res. 2006; 23: 2417–26.
- Rumondor AC, Ivanisevic I, Bates S, Alonzo DE, Taylor LS. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res. 2009; 26: 2523–34.
- Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res. 1995; 12: 799–806.
- Liu R. Water insoluble drug formulation. CRC Press, Taylor & Francis group, New York, USA. 2008. pp. 133-467.
- Sinha S, Baboota S, Ali M, Kumar A, Ali J. Solid Dispersion: An alternative technique for bioavailability enhancement of poorly soluble drugs. Journal of Dispersion Science and Technology, 2009; 30: 1458–73.
- Durga Maheswari Parvataneni, Mitrabhanu Mohanty, Venkata Satyanarayana Appadwedula et al. Pharmaceutical compositions comprising phenylaminopyrimidine derivative. WO2017103941 A1 2017.
- Higa G M and Abraham J. Lapatinib in the treatment of breast cancer. Expert review of anticancer therapy, 2007; 7 (9): 1183–1192.
- Geyer C E, Forster J, Lindquist D et al., Lapatinib plus capecitabine for HER2-positive advanced breast cancer, New England Journal of Medicine, 2006; 355 (26): 2733–2743.
- Johnston S, Pippen J. Jr., Pivot X. et al., Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology, 2009; 27 (33), 5538–5546.
- Burris III H A, Taylor C. W, Jones S. F. et al., A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clinical Cancer Research, 2009; 15(21), 6702–6708.
- Devriese L A, Koch K. M, Mergui-Roelvink M. et al. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Investigational New Drugs, 2014; 32 (3): 481–488.
- Koch K. M, Im Y.H, Kim S.B. et al., Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients, Clinical Pharmacology in Drug Development. 2013; 2(4), 336–341.
- Maniruzzaman M, Morgan DJ, Mendham AP, Pang J, Snowden MJ, Douroumis D. Int. J. Pharm. 2013; 443(1–2):199–208.
- Mohanty Mitrabhanu et al. Novel techniques to prepare solid dispersions to improve solubility of bosentan. J Pharm Res, 2017; 6(12): 215-224.
- Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharmaceutical Technology. 1996; 20: 64-74.
- Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002; 231: 131-144.
- Ford JL. The current status of solid dispersions. Pharm Acta Helv. 1986; 61: 69–88.
- Gauzman HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2009; 96:2686–702.
- Chauhan H, Hui-Gu C, Atef E. Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci. 2013; 102: 1924–35.
- Usui F, Maeda K, Kusai A, Nishimura K, Keiji Y. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int J Pharm. 1997; 154: 59–66.
- Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm. 2001; 212: 213–21.
- Simonelli AP, Mehta SC, Higuchi WI. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci. 1970; 59: 633-38.
- Ziller KH, Rupprecht H. Control of crystal growth in drug suspensions. Drug Dev Ind Pharm. 1988; 14: 2341-70.
- Bevernage J, Forier T, Brouwers J, Tack J, Annaert P, Augustijns P. Excipient-mediated supersaturation stabilization in human intestinal fluids. Mol Pharm. 2011; 8: 564–70.
- Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, et al. Characterization and optimization of AMG-517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci. 2009; 98: 516–28.
- Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm. 2008; 34: 890–902.
- Balani PN, Wong SY, Ng WK, Widjaja E, Tan RB, Chan SY. Influence of polymer content on stabilizing milled amorphous salbutamol sulphate. Int J Pharm. 2010; 391 :125–36.
- Xie S, Poornachary SK, Chow PS, Tan RB. Direct precipitation of micron-size salbutamol sulfate: new insights into the action of surfactants and polymeric additives. Cryst Growth Des. 2010; 10: 3363–71.
- Yani Y, Chow PS, Tan RB. Molecular simulation study of the effect of various additives on salbutamol sulfate crystal habit. Mol Pharm. 2011; 8: 1910–8.
- Ilevbare GA, Liu H, Edgar KJ, Taylor LS. Maintaining supersaturation in aqueous drug solutions: impact of different polymers on induction times. Cryst Growth Des 2012; 13: 740–51.
- Tian F, Saville DJ, Gordon KC, Strachan CJ, Zeitler JA, Sandler N, et al. The influence of various excipients on the conversion kinetics of carbamazepine polymorphs in aqueous suspension. J Pharm Pharmacol. 2007; 59: 193–201.
- Dai WG, Dong LC, Li S, Deng ZY. Combination of pluronic/vitamin E TPGS as a potential inhibitor of drug precipitation. Int J Pharm 2008; 355: 31–7.
- Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci. 2007; 30: 367-74.
- Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties. Eur J Pharm Biopharm. 2009; 71: 109–16.
- Ilevbare GA, Liu H, Edgar KJ, Taylor LS. Understanding polymer properties important for crystal growth inhibition: impact of chemically diverse polymers on solution crystal growth of ritonavir. Cryst Growth Des. 2012; 12: 3133–43.
- Kramarenko EY, Winkler RG, Khalatur PG, Khokhlov AR, Reineker P. Molecular dynamics simulation study of adsorption of polymer chains with variable degree of rigidity. I: static properties. J Chem Phys. 1996; 104: 4806–13.
- Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008; 5: 1003–19.
- Akiyama Y, Yoshioka M, Horibe H, Hirai S, Kitamori N, Toguchi H. pH- independent controlled-release microspheres using polyglycerol ester-fatty acids. J Pharm Sci. 1994; 83: 1600–1607.